Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bio Path Holdings Inc

Current price
4.29 USD +0.04 USD (+0.94%)
Last closed 4.2 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 299 074 USD
Yield for 12 month +198.33 %
21.11.2021 - 28.11.2021

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas. Address: 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

40 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-178 000 USD

Last Year

-178 000 USD

Current Quarter

-41 000 USD

Last Quarter

-46 000 USD

Key Figures BPTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -15 761 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -103.19 %
PEG Ratio
Return On Equity TTM -220.02 %
Wall Street Target Price 40 USD
Revenue TTM
Book Value 0.71 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings Share -33.63 USD
Diluted Eps TTM -33.63 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BPTH

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BPTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 23.02.2024
Dividend Date 18.01.2019

Stock Valuation BPTH

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.0868
Price Book MRQ 5.2133

Financials BPTH

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BPTH

For 52 weeks

2.94 USD 44.8 USD
50 Day MA 6.02 USD
Shares Short Prior Month 63 353
200 Day MA 10.7 USD
Short Ratio 1.34
Shares Short 67 406
Short Percent 9.96 %

Dynamics of changes in the value of assets




399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds



207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics



2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics